// App-Quantinova.ai

3036 : Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma

Researchers

Presenter

  • Neelesh Sharma

Principal Investigators

  • Josephine Dermawan

  • Andrei Purmal

  • Daniel Lindner

  • Gary Wildey

  • Afshin Dowlati

  • Andrei Gudkov

  • Katerina Gurova

  • George R. Stark

Medical Centers

  • University Hospitals Seidman Cancer Center, Case Western Reserve University, and Case Comprehensive Cancer Center, Cleveland, OH

  • Lerner Research Institute, Cleveland Clinic, Cleveland, OH.

  • Cleveland Biolabs, Buffalo, NY

  • Cleveland Clinic, Cleveland, OH

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Nuclear factor kappa-light-chain-enhancer of activated B cells

  • Hepatocyte growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • Afatinib

  • L-Tyrosine

  • CBL-0137

  • Curaxin

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved